Open Access
Review Article
September-October 2026, Vol. 02 (5), 12-26
International Journal of Pharmaceutical
Research and Medicinal Plants
(An International Peer Reviewed Journal)
Hepatotoxicity and Nephrotoxicity of Widely Used Medicinal Herbs: A
Critical Appraisal of Safety Evidence against the Assumption that
“Natural” Means Safe
Niranjan Giri
*
and Umesh Maske
Master of Pharmacy (Pharmaceutics), Department of Pharmaceutics, Mangaldeep Institute of Pharmacy,
Chhatrapati Sambhajinagar, Maharashtra, India
ARTICLE INFO:
ABSTRACT
Received:
16
th
Sept.
2026
;
Received
in
revised form: 22
nd
Sept. 2026
; Accepted:
28
th
Sept.
2026
;
Available
online:
25
th
Oct. 2026.
Keywords:
Herbal hepatotoxicity; Herb-
induced liver injury; Nephrotoxicity;
Aristolochic acid; Medicinal Plants;
Pharmacovigilance; Herb–drug
interaction; Quality control.
DOI:
https://doi.org/10.61280/89qdmp44
*Corresponding Author:
Niranjan Giri
Email:
niranjangiri009@gmail.com
Herbal medicines are used by a large share of the world’s population.
Many people believe these medicines are safe because they come from
plants.. The published literature has not kept up with this belief. There
are studies on the effectiveness
of medicinal plants.. Data on safety
especially
for
the
liver
and
kidneys
are
not
easy
to
find.
They
are
spread out across case reports, pharmacovigilance systems and a few
registry studies. These data are rarely gathered in a way.This narrative
review
looks
at
the
evidence
on
liver
and
kidney
damage
linked
to
used herbal medicines. It tests the idea that "natural" means safe. The
review
includes
literature
from
databases.
The
evidence
was
graded
based
on
study
type,
causality
assessment
and
biological
plausibility.The review covers the patterns of liver injury caused by
herbs.
It
discusses
the
ways
herbs
can
harm
the
liver
and
kidneys.
These include forming chemicals causing oxidative stress, damaging
mitochondria,
triggering
immune
reactions
harming
kidney
tubules
and damaging DNA. It also identifies herbs that have strong signals
for harm. These include Aristolochia species, green tea extract, kava,
turmeric,
ashwagandha,
Tinospora
cordifolia,
plants
containing
pyrrolizidine alkaloids and Garcinia cambogia.The review also looks
at
how
problems
like
contamination,
heavy
metals
and
interactions
with medicines make it harder to confirm cause and effect. Four key
gaps stand out. First harms are often not reported in studies that look
at
effectiveness.
Second
many
studies
do
not
assess
causality
well.
Third herbal products are not standardized. Fourth there is monitoring
of
kidney
function.The
review
ends
with
advice
for
researchers,
doctors and regulators. It stresses the need, for safety data better study
methods
and
stronger
oversight.
The
message
is
clear:
just
because
something is natural does not mean it is safe.
Copyright:
©
Author
2026
by
the
Author.
International
Journal
of
Pharmaceutical
Research
and
Medicinal
Plants
Published
by
Informative Journals
(Jadoun Science Publishing Group India). This article is an open access article distributed under the terms and conditions
of the CC BY-NC-ND 4.0 International License (http://creativecommons.org/licenses/by-nc-nd/4.0/)
https://informativejournals.com/journal/index.php/Journal_Medicinal_Plants
Page | 12
1. INTRODUCTION
I think Plants have provided medicines for long as written records exist and in many countries Plants still are
the first
choice for treatment.
The
World
Health Organization reports that
traditional
and complementary
medicine is practiced in every member state and a large share of people in low- and middle-income regions
rely on Plants for their main care (WHO, 2019). In India, Ayurvedic, Siddha and Unani preparations are used
with and sometimes instead of, standard treatment. The same pattern appears in Europe and North America
where botanical
supplements are sold
over the counter
and are often taken without advice. A
belief runs
through much of this use: what is natural cannot do harm. The belief is understandable. It is not supported by
toxicology.
Many
of
the
poisons
and
drugs
that
doctors
use
are
made
from
Plants
and
Plants
create
the
chemicals that help them defend themselves not to help humans (Ernst, 1998). A herb that works enough to
treat
disease
can
also
injure
body
tissue
especially
if
taken
in
high
amounts
used
for
a
long
time
or
by
someone who is sensitive. The liver and the kidney are the two organs most exposed to this danger. The liver
takes
in.
Changes
most
plant
chemicals
that
people
swallow
and
while
doing
this
the
liver
can
produce
harmful intermediates. The kidney removes these chemicals and their breakdown products and the kidneys
tubular cells are exposed to high local amounts (Isnard Bagnis et al., 2004; Luyckx and Naicker, 2008). Both
the liver and the kidney often fail without warning until damage is large. The evidence for safety is uneven.
Effectiveness is studied in lab tests and small clinical trials. Those trials are often not set up or large enough
to
find
rare
side
effects.
Harms
are
reported
thoroughly
than
benefits
in
randomised
trials
in
general
(Ioannidis et al., 2004) and herbal trials are no exception. Reviews of side effects of medicines repeatedly
point out that most information comes from case reports that vary in quality (Posadzki et al., 2013). As a
result doctors and patients often cannot tell a herbal poison from a contaminated or mixed product or from a
cause that is not related to plants for liver or kidney injury. Several good reviews already cover liver damage
(Stickel and Shouval 2015; Teschke et al. 2013; Philips et al. 2020; Patel-Rodrigues et al. 2024) and kidney
damage, from Chinese herbal medicine (Yang et al. 2018). It is less common to find one review that looks at
both the liver and the kidney together that rates how strong the evidence is of only listing plants and that asks
directly why the safety information is so sparse. That is the purpose of this review.
2. REVIEW METHODOLOGY
This is a review that used a structured search, not a systematic review or a meta-analysis. PubMed, Scopus,
Web of Science and Google Scholar were searched for articles published up to 2025 using combinations of
the
terms:
"herb-induced
liver
injury"
"herbal
hepatotoxicity"
"herbal
nephrotoxicity"
"aristolochic
acid
nephropathy" "dietary supplement
liver injury"
"Ayurvedic hepatotoxicity" "herbal
contamination"
"herb–
drug interaction" and "pharmacovigilance herbal". The reference lists of reviews and clinical guidelines were
also checked.Registry studies, consensus guidelines, systematic reviews, case series and mechanistic studies
were given priority. Single case reports were used mainly to show a signal or to describe a situation. Articles
were not
included when the herbal
exposure was not
clear or when the report did
not
explain how other
causes of injury were ruled out.Because herb-related case reports vary a lot in quality the evidence for each
herb was graded by the authors in a way (Table 1). The grading looked at (a) whether causality was checked
using a tool, like the Roussel Uclaf Causality Assessment Method (RUCAM) (Danan and Teschke 2016) (b)
the
number
of
independent
reports
and
whether
registry
data
are
available
(c)
whether
the
product
was
chemically checked and (d) whether there is a biological reason to believe it could cause harm. This grading
is a judgment made for this review is not a scale that has been tested.
3. WHY “NATURAL” DOES NOT MEAN “SAFE”
Three distinct ideas are often blurred in public discussion, and separating them clarifies the problem.
Niranjan Giri
/
International Journal of Pharmaceutical Research and Medicinal Plants
2026, Vol. 2 (5), 12-26
https://informativejournals.com/journal/index.php/Journal_Medicinal_Plants
Page | 13
Origin is not safety.
Arsenic, strychnine, digitalis glycosides and aristolochic acid are all natural. Toxicity
depends on structure, dose, exposure duration and host factors, not on whether a compound was extracted
from a plant or synthesised.
Long
traditional
use
is
not
proof
of
safety.
Traditional use shows that a preparation is not acutely and
obviously lethal when made the way it was traditionally done. That doesn’t mean it’s safe from delayed or
harm. Also it doesn’t say anything about versions. In the past these preparations were often boiled, fermented
or mixed with herbs. Each of those steps changes the chemical makeup. Today capsules and extracts focus on
one part of the plant at much higher doses than what was used in traditional recipes. The kava story is an
example. For generations people in Pacific communities drank liquid made from kava roots. Rarely had liver
problems. Later organic-solvent extracts of kava were sold as supplements, in Europe and linked to serious
liver issues. This led to rules and restrictions (Teschke et al. 2012).
Absence
of
reports
is
not
absence
of
harm.
Without
systematic
surveillance,
uncommon
harms
are
invisible. Idiosyncratic liver injury may occur in only a few per 10,000 or 100,000 exposed people, which no
herbal efficacy trial is large enough to detect (Andrade et al., 2023).
4. EPIDEMIOLOGY OF HERB-INDUCED LIVER AND KIDNEY INJURY
4.1 Liver
The trustworthy information comes from studies that follow people over time. In the United States Drug-
Induced Liver Injury Network (DILIN) dietary supplements made up about 9% of confirmed cases in the
early group (Navarro et al., 2014) and the percentage went up from around 7% to 20% between the first and
later groups (Navarro et al., 2017). Bodybuilding products and multi-ingredient supplements were a reason
for the increase and cases linked to multi-ingredient products were often more serious.In mainland China a
big
countrywide study found that herbal
and dietary supplements caused about
a quarter of drug-induced
liver injury cases (Shen et al. 2019). In India the data also shows the trend. Single-center studies show that
traditional and alternative preparations play a role in drug-induced liver injury, including serious cases with
acute-on-chronic liver failure (Devarbhavi et
al., 2010; Philips et al. 2018). The Indian situation is tricky
because of -herb mixtures with unknown ingredients and people using medicines on their own both of which
make it hard to determine what caused the injury.These numbers need to be looked at. The way cases are
defined the way products are checked and the way they are used in areas can be different so they can't be
compared directly. They do show that liver injury, from herbs is an growing cause of liver disease and not
something rare.
4.2 Kidney
I find that renal data are much weaker. There is no registry like DILIN for the kidney. Most of what we know
comes from case series, clinic notes and a few population studies. In sub-Saharan Africa and South Asia
reviews say that traditional medicines can cause kidney injury, in some hospitals (Luyckx and Naicker 2008;
Jha,
2010).
Chronic
kidney
injury
is
even
harder
to
pin
down
because
kidney
disease
grows
slowly
and
doctors
rarely
ask
about
herb
use.
The
well-known
kidney
disease
caused
by
herbs
is
aristolochic
acid
nephropathy, which only came to light after a group of patients had fast-moving kidney failure in a Belgian
slimming clinic in the early 1990s (Vanherweghem et al., 1993).
5. MECHANISMS OF HERBAL HEPATOTOXICITY AND NEPHROTOXICITY
The principal mechanisms are summarised in Figure 1. They are not mutually exclusive, and one herb can act
through several.
Niranjan Giri
/
International Journal of Pharmaceutical Research and Medicinal Plants
2026, Vol. 2 (5), 12-26
https://informativejournals.com/journal/index.php/Journal_Medicinal_Plants
Page | 14
Figure
1.
Principal
pathways
of
herb-induced
liver
and
kidney
injury.
PAs,
pyrrolizidine
alkaloids;
AA,
aristolochic
acid;
SOS,
sinusoidal
obstruction
syndrome;
AKI,
acute
kidney
injury;
CKD,
chronic
kidney
disease.
5.1 Hepatic mechanisms
Reactive metabolite formation.
Cytochrome P450 enzymes convert some phytochemicals into electrophilic
metabolites that bind covalently to proteins and deplete glutathione. Pennyroyal oil, which contains pulegone,
is a classic example. Its metabolite menthofuran causes centrilobular necrosis, and cases of fatal injury have
been
reported
(Anderson
et
al.,
1996).
The
furan-containing
diterpenoids
in
germander
(
Teucrium
chamaedrys
) act in a similar way (Larrey et al., 1992).
Oxidative stress and mitochondrial injury.
Drug-induced liver injury commonly involves mitochondrial
dysfunction, loss of membrane potential and an increase in reactive oxygen species, leading to hepatocyte
death (Jaeschke et al., 2012). Usnic acid, an uncoupler of oxidative phosphorylation found in lichen-based
weight-loss products, was linked to acute liver failure (Favreau et al., 2002).
Pyrrolizidine
alkaloid
toxicity.
Plants
containing
1,2-unsaturated
pyrrolizidine
alkaloids,
such
as
Symphytum
,
Senecio
and
Crotalaria
species,
are
metabolised
to
pyrrolic
derivatives
that
damage
hepatic
sinusoidal
endothelial
cells,
producing
sinusoidal
obstruction
syndrome
(hepatic
veno-occlusive
disease)
(Chen and Huo, 2010; Wiedenfeld, 2011).
Immune-mediated and idiosyncratic injury.
Many cases of herbal liver injury are unpredictable, with a
latency
of
weeks
to
months
and
features
suggestive
of
hypersensitivity
or
autoimmunity.
Genetic
susceptibility is increasingly recognised: green tea extract and
Polygonum multiflorum
injury have both been
associated
with
the
HLA-B*35:01
allele
(Hoofnagle
et
al.,
2021).
Autoimmune-like
hepatitis
has
been
described after the use of
Tinospora cordifolia
(Nagral et al., 2021).
Cholestatic
injury.
Some
herbal
products
impair
bile
acid
transport
and
secretion,
giving
a
prolonged
cholestatic picture, as described in several Ayurvedic and weight-loss product reports (Philips et al., 2020).
5.2 Renal mechanisms
Direct tubular toxicity.
The proximal tubule is the main site of injury, because it takes up and concentrates
xenobiotics.
Aristolochic
acids
are
transported
into
proximal
tubular
cells,
where
they
cause
cell
death,
Niranjan Giri
/
International Journal of Pharmaceutical Research and Medicinal Plants
2026, Vol. 2 (5), 12-26
https://informativejournals.com/journal/index.php/Journal_Medicinal_Plants
Page | 15
interstitial inflammation and progressive fibrosis (Debelle et al., 2008). Atractyloside, the toxin in
Callilepis
laureola
(impila), inhibits the mitochondrial ADP/ATP carrier and produces both renal tubular and hepatic
necrosis (Popat et al., 2001).
Genotoxicity and carcinogenicity.
Aristolochic acid forms DNA adducts, and the characteristic A:T to T:A
transversions in the
TP53
gene link exposure to upper urinary tract urothelial carcinoma (Grollman et al.,
2007; Chen et al., 2012). This long-term cancer risk persists after kidney failure is established (Nortier et al.,
2000).
Electrolyte
and
haemodynamic
effects.
Glycyrrhizin
in
liquorice
inhibits
11β-hydroxysteroid
dehydrogenase type 2, producing a syndrome of apparent mineralocorticoid excess with hypokalaemia and
hypertension. Prolonged hypokalaemia can itself injure the kidney (Omar et al., 2012).
Crystal deposition, volume depletion and rhabdomyolysis.
Some herbs and plant foods contribute to acute
kidney injury by oxalate crystal formation, by intravascular volume depletion through purgative effects, or
through myoglobin released from muscle injury (Luyckx and Naicker, 2008; Yang et al., 2018).
Heavy-metal
nephrotoxicity.
Lead, mercury, arsenic and cadmium in contaminated products damage the
proximal tubule and the glomerulus (see Section 8) (Ernst, 2002).
6. HEPATOTOXICITY OF INDIVIDUAL HERBS: APPRAISAL OF THE EVIDENCE
Table
1
summarises
the
herbs
with
the
most
substantial
published
signal
for
liver
injury
and
gives
a
qualitative assessment of evidence strength. A few merit further comment.
Green
tea
extract
(
Camellia
sinensis
).
Brewed
green
tea
has
rarely
been
implicated,
but
concentrated
extracts providing high doses of epigallocatechin gallate (EGCG) have been linked to hepatocellular injury,
in some cases severe (Mazzanti et al., 2009). The European Food Safety Authority concluded that EGCG
intake of 800 mg
per day or more
from
supplements was
associated with increased serum transaminases
(EFSA Panel on Food Additives and Flavourings, 2018). The risk appears dose- and formulation-dependent,
and is higher when concentrated extracts are taken on an empty stomach (Sarma et al., 2008).
Turmeric and curcumin (
Curcuma longa
).
Turmeric has a long culinary history, and curcumin has been
studied in many trials without major safety concerns, which is why recent liver injury reports surprised many
clinicians. DILIN investigators described cases linked to turmeric supplements, a number of which involved
formulations with enhanced bioavailability (for example, with piperine) and several of which carried HLA-
B*35:01 (Halegoua-DeMarzio et al., 2023). The lesson is that a safe food spice cannot be assumed to be a
safe concentrated supplement.
Ashwagandha (
Withania somnifera
).
Ashwagandha is widely promoted as an adaptogen. A case series from
Iceland and the DILIN registry documented cholestatic and mixed liver injury with a latency of a few weeks
to months, with generally good recovery after withdrawal, although jaundice was prolonged in some patients
(Björnsson et al., 2020).
Giloy
or
guduchi
(
Tinospora
cordifolia
).
Use
of
this
herb
as
an
“immunity
booster”
increased
sharply
during the COVID-19 pandemic in India. Clinicians then reported cases of acute hepatitis, often resembling
autoimmune hepatitis, some of which progressed to liver failure (Nagral et al., 2021; Philips et al., 2020).
Kava
(
Piper methysticum
).
Reports of severe liver injury, including transplantation, led several European
countries to restrict kava products in the early 2000s. Whether the risk lies in the plant, in the extraction
solvent, in poor-quality plant parts, or in drug interactions is still debated (Teschke et al., 2012).
Garcinia cambogia.
Weight-loss products containing hydroxycitric acid have been linked to acute hepatitis
and
liver
failure,
although
most
products
also
contain
other
ingredients,
which
complicates
attribution
(Crescioli et al., 2018).
Niranjan Giri
/
International Journal of Pharmaceutical Research and Medicinal Plants
2026, Vol. 2 (5), 12-26
https://informativejournals.com/journal/index.php/Journal_Medicinal_Plants
Page | 16
Black
cohosh
(
Actaea
racemosa
).
A
causal
link
to
liver
injury
remains
controversial.
When
initially
suspected
cases
were
reassessed
with
structured
causality
criteria
and
product
analysis,
the
evidence
for
causality was judged weak or doubtful in many of them (Teschke et al., 2011). This is a good example of
why
rigorous
causality
assessment
matters
in
both
directions:
it
prevents
both
false
alarms
and
false
reassurance.
Other herbs.
Chaparral (
Larrea tridentata
) (Sheikh et al., 1997), germander (Larrey et al., 1992), noni juice
(
Morinda citrifolia
) (Yüce et al., 2006) and pyrrolizidine-containing preparations (Chen and Huo, 2010) all
have documented cases. Large compilations of case reports list many additional plants, although the quality
of the reports varies widely (Teschke et al., 2012; Brown, 2017).
Table 1. Selected medicinal herbs associated with hepatotoxicity, with qualitative evidence grading
|
Herb
(botanical
name)
|
Suspected
constituent
|
Pattern / mechanism
|
Evidence
strength*
|
Key references
|
|
Green
tea
extract
(
Camellia
sinensis
)
|
EGCG and catechins
|
Hepatocellular;
dose-
dependent;
HLA-
B*35:01 association
|
Strong
(registry,
regulatory
assessment)
|
Mazzanti
et
al.,
2009; EFSA Panel,
2018; Hoofnagle et
al., 2021
|
|
Turmeric
/
curcumin
(
Curcuma longa
)
|
Curcuminoids
(enhanced-
absorption products)
|
Hepatocellular;
immune-mediated
|
Moderate
(case
series, registry)
|
Halegoua-
DeMarzio
et
al.,
2023
|
|
Ashwagandha
(
Withania
somnifera
)
|
Withanolides
(not
confirmed)
|
Cholestatic
or
mixed;
idiosyncratic
|
Moderate
(case
series)
|
Björnsson
et
al.,
2020
|
|
Giloy
(
Tinospora
cordifolia
)
|
Not established
|
Hepatocellular;
autoimmune-like
|
Moderate
(case
series)
|
Nagral et al., 2021
|
|
Kava
(
Piper
methysticum
)
|
Kavalactones
|
Hepatocellular;
possible
solvent
or
quality effect
|
Moderate
to
strong
(regulatory
action)
|
Teschke
et
al.,
2012
|
|
Pyrrolizidine
plants
(
Symphytum
,
Senecio
)
|
1,2-unsaturated
pyrrolizidine
alkaloids
|
Sinusoidal
obstruction syndrome
|
Strong
(mechanistic
and clinical)
|
Chen
and
Huo,
2010;
Wiedenfeld,
2011
|
|
Germander
(
Teucrium
chamaedrys
)
|
Furano-diterpenoids
|
Hepatocellular;
reactive metabolites
|
Moderate
(case
series)
|
Larrey et al., 1992
|
|
Pennyroyal
oil
(
Mentha
pulegium
)
|
Pulegone
/
menthofuran
|
Centrilobular necrosis
|
Moderate
(case
reports,
mechanism)
|
Anderson
et
al.,
1996
|
|
Garcinia
cambogia
|
Hydroxycitric
acid
(confounded)
|
Hepatocellular;
acute
liver failure
|
Limited
to
moderate
(multi-
ingredient
|
Crescioli
et
al.,
2018
|
Niranjan Giri
/
International Journal of Pharmaceutical Research and Medicinal Plants
2026, Vol. 2 (5), 12-26
https://informativejournals.com/journal/index.php/Journal_Medicinal_Plants
Page | 17
|
Herb
(botanical
name)
|
Suspected
constituent
|
Pattern / mechanism
|
Evidence
strength*
|
Key references
|
|
products)
|
|
Chaparral
(
Larrea
tridentata
)
|
Nordihydroguaiaretic
acid
|
Hepatocellular
and
cholestatic
|
Moderate
(case
series)
|
Sheikh et al., 1997
|
|
Black
cohosh
(
Actaea racemosa
)
|
Unclear
|
Hepatocellular;
causality disputed
|
Weak
to
doubtful
after
reassessment
|
Teschke
et
al.,
2011
|
*Qualitative
grading
by
the
authors
based
on
study
design,
structured
causality
assessment,
number
of
independent reports and biological plausibility. It is not a validated scale.
7. NEPHROTOXICITY OF INDIVIDUAL HERBS: APPRAISAL OF THE EVIDENCE
Aristolochia
species
and
aristolochic
acid.
This is the characterised herbal kidney toxin. Young women
who visited a clinic got fast worsening kidney scarring after taking a weight-loss plan that mistakenly used
Aristolochia
fangchi
instead
of
a
Chinese
herb
because
the
names
sounded
alike
(Vanherweghem
et
al.,
1993). Some of those women later developed bladder cancer (Nortier et al., 2000). Aristolochic acid has also
been
linked
to
endemic
kidney
disease
when
wheat
was
contaminated
with
Aristolochia
clematitis
seeds
(Grollman et al., 2007) and to the high rate of upper urinary tract cancer, in Taiwan (Chen et al., 2012). Even
though the danger of acid has been known for thirty years products that contain aristolochic acid are still sold
in some places and the problem is now seen as global (Debelle et al., 2008).
Callilepis laureola (impila).
This southern African herb contains atractyloside. Poisoning produces hepatic
and renal tubular necrosis, with high mortality, and it is a reminder that a single plant can injure both organs
at once (Popat et al., 2001).
Liquorice
(
Glycyrrhiza
glabra
).
Chronic
high
intake
of
glycyrrhizin-containing
products
leads
to
hypokalaemia, hypertension and, in severe cases, rhabdomyolysis and renal impairment (Omar et al., 2012).
The
risk
is
mainly
with
excess
consumption
of
confectionery,
tonics
and
supplements,
and
not
with
occasional use.
Other
plants
and
preparations.
Reviews
of
Chinese
herbal
medicine
identify
several
additional
agents
linked
to
acute
kidney
injury
or
interstitial
nephritis,
as
well
as
contamination
with
heavy
metals
and
undeclared pharmaceuticals (Shaw, 2010; Yang et al., 2018). Ayurvedic
rasa shastra
preparations, which
deliberately incorporate processed metals, are a particular concern for both renal and hepatic safety (Saper et
al.,
2008).
Evidence
for
many
suspected
nephrotoxic
herbs,
however,
rests
on
isolated
reports,
and
renal
biopsy data are often missing.
Table 2. Selected herbs and herbal products associated with nephrotoxicity
|
Herb / product
|
Toxic agent
|
Renal lesion / mechanism
|
Evidence strength*
|
Key references
|
|
Aristolochia
species
|
Aristolochic
acids I and II
|
Proximal
tubular
injury,
interstitial
fibrosis,
DNA
adducts,
urothelial
carcinoma
|
Strong
(clinical,
epidemiological,
mechanistic)
|
Vanherweghem
et
al., 1993; Nortier et
al.,
2000;
Debelle
et al., 2008
|
|
Callilepis
laureola
|
Atractyloside
|
Tubular
necrosis;
mitochondrial
ADP/ATP
carrier inhibition
|
Moderate
(case
series)
|
Popat et al., 2001
|
|
Liquorice
|
Glycyrrhizin
|
Hypokalaemia,
|
Moderate
to
strong
|
Omar et al., 2012
|
Niranjan Giri
/
International Journal of Pharmaceutical Research and Medicinal Plants
2026, Vol. 2 (5), 12-26
https://informativejournals.com/journal/index.php/Journal_Medicinal_Plants
Page | 18
|
Herb / product
|
Toxic agent
|
Renal lesion / mechanism
|
Evidence strength*
|
Key references
|
|
(
Glycyrrhiza
glabra
)
|
hypertension,
secondary
renal injury
|
(clinical,
mechanistic)
|
|
Metal-
containing
Ayurvedic
preparations
|
Lead,
mercury,
arsenic
|
Tubular
and
glomerular
toxicity
|
Moderate
(product
analysis;
limited
clinical linkage)
|
Saper
et
al.,
2008;
Ernst, 2002
|
|
Various
Chinese
herbal
products
|
Variable,
including
adulterants
|
Acute
kidney
injury,
interstitial nephritis
|
Variable;
often
weak
|
Shaw,
2010;
Yang
et al., 2018
|
*Qualitative grading by the authors; not a validated scale.
8. CONTAMINATION, ADULTERATION AND PRODUCT QUALITY
In cases the problem is not the herb that the label claims but what else the herb product contains. I have read
a study of medicines sold online that found about one in five products contained detectable lead, mercury or
arsenic and some exceeded daily intake limits (Saper et al., 2008). Heavy metals themselves are known to be
toxins
for
the
liver
and
kidneys
(Ernst,
2002).Adding
to
this
risk
are
adulteration,
with
drugs,
microbial
contamination, mycotoxins and pesticide residues (Posadzki et al., 2013; WHO, 2007). Species substitution is
another problem. DNA barcoding of supplements sold in North America showed that most contained plant
material not declared on the label and that fillers and substitutes were common (Newmaster et al., 2013).
When a product
is
mislabelled, any case report that follows is
attributed to
the plant, which corrupts
the
whole safety literature.The practical consequence is that a published case of "herb X hepatotoxicity" cannot
be trusted unless the herb product was chemically authenticated and tested for contaminants. Few reports
meet this standard.
Table 3. Quality problems that confound herbal safety evidence
|
Problem
|
Example
|
Consequence
for
safety
assessment
|
Key references
|
|
Heavy-metal
contamination
|
Lead,
mercury,
arsenic
in
Ayurvedic products
|
Hepatic
and
renal
injury
attributed to the herb rather than
the metal
|
Saper
et
al.,
2008;
Ernst, 2002
|
|
Species
substitution
and mislabelling
|
Undeclared
plants
and
fillers in supplements
|
Wrong
plant
implicated
in
case
reports
|
Newmaster
et
al.,
2013
|
|
Adulteration
with
pharmaceuticals
|
Undeclared
synthetic
drugs
|
Drug
toxicity
misattributed
to
the herb
|
Posadzki
et
al.,
2013
|
|
Microbial
and
chemical contaminants
|
Mycotoxins, pesticides
|
Additional hepatotoxic exposure
|
WHO, 2007
|
|
Non-standardised
extracts
|
Variable
marker
content
between batches
|
Dose cannot be reconstructed or
compared
|
Ekor, 2014
|
Niranjan Giri
/
International Journal of Pharmaceutical Research and Medicinal Plants
2026, Vol. 2 (5), 12-26
https://informativejournals.com/journal/index.php/Journal_Medicinal_Plants
Page | 19
9. HERB–DRUG INTERACTIONS
Patients rarely take herbs by themselves. Many people use them with prescription medicines and some herbs
can either increase or decrease the activity of cytochrome P450 enzymes and transporters which changes how
much of a drug is in the body (Izzo and Ernst, 2009). This situation has two effects. First a herb can make the
liver or kidney damage caused by a regular medicine worse for example by increasing the amount of a drug
that has a range between a helpful dose and a harmful dose. Second when someone is taking medicines at the
same time it is hard to tell which one caused any harm. A case where ashwagandha was linked to harm in a
person also taking propranolol and alprazolam shows this problem clearly (Philips et al. 2020). Collecting
information,
about
all
the
medicines
being
taken
along
with
herbs
is
very
important.
This
is
rarely
done
properly.
10. DIAGNOSTIC AND CAUSALITY CHALLENGES
Diagnosing herbal liver injury is a diagnosis of exclusion. Viral hepatitis, alcohol, autoimmune and metabolic
liver disease, biliary obstruction and other drugs must be excluded. International guidelines recommend a
structured approach and the use of causality tools such as RUCAM (Danan and Teschke, 2016; EASL, 2019;
Chalasani et al., 2021). Even so, applying RUCAM to herbal products is difficult, because the exposure is
often poorly documented and the product cannot be re-tested. Teschke and Eickhoff (2015) argue that many
published cases fail minimum quality criteria, including adequate exclusion of alternative causes and product
analysis.
For the kidney, no equivalent, widely accepted causality instrument exists, and renal biopsy is not routinely
performed. Early renal injury is often missed because serum creatinine rises late, and herbal exposure is not a
routine
question
in
a
nephrology
history.
A
suggested
approach
to
evaluating
suspected
herbal
injury
is
shown in Figure 2.
Figure 2.
Suggested approach to evaluating suspected herb-induced liver or kidney injury. RUCAM, Roussel
Uclaf Causality Assessment Method. Evaluation of suspected herbal injury · 6 steps, 1 decision
11. REPORTING GAPS, PHARMACOVIGILANCE AND REGULATION
The central point of this review is that herbal safety evidence is incomplete in a structural way. Four gaps
stand out.
-
1.
Harms
are
under-reported
in
efficacy
studies.
Trials
of
herbal
products
are
usually
designed
around efficacy outcomes, with small samples and short follow-up. Reporting of harms in trials is
generally weaker than reporting of benefits (Ioannidis et al., 2004), and liver and kidney function are
not always monitored.
Niranjan Giri
/
International Journal of Pharmaceutical Research and Medicinal Plants
2026, Vol. 2 (5), 12-26
https://informativejournals.com/journal/index.php/Journal_Medicinal_Plants
Page | 20
-
2.
Spontaneous reporting is weak.
Patients rarely tell clinicians about herbal use, and clinicians rarely
report suspected herbal reactions. Many countries lack pharmacovigilance systems that can capture
herbal
adverse
events
(Ekor,
2014).
The
WHO
has
issued
guidance
on
integrating
herbal
safety
monitoring into national systems (WHO, 2004), but implementation is uneven.
-
3.
Case
reports
are
heterogeneous.
Many
do
not
identify
the
plant
by
botanical
name,
verify
the
product, record the dose and duration, or exclude other causes (Teschke and Eickhoff, 2015).
-
4.
Renal surveillance is almost absent.
Hepatic registries exist for drug-induced liver injury, but there
is nothing comparable for herb-induced kidney injury.
Regulation
differs
widely
between
countries.
In
some
jurisdictions
herbal
products
are
classified
as
food
supplements,
with
lighter
requirements
for
safety
evidence
than
for
medicines,
and
in
others
they
are
regulated as traditional medicines. This inconsistency allows products with a documented signal to remain on
the market in one country while restricted in another, as happened with kava (Teschke et al., 2012).
12. RESEARCH GAPS AND FUTURE DIRECTIONS
Based on the evidence reviewed, the following gaps deserve priority:
-
1.
Prospective,
multi-centre
registries
of
herb-induced
liver
and
kidney
injury
that
require
chemical
verification of the implicated product.
-
2.
Standardised
case-report
templates
that
capture
botanical
identity,
extract
type,
dose,
duration,
concomitant drugs and exclusion of alternative causes.
-
3.
Inclusion of liver and kidney biomarkers, and pre-specified harm reporting, in clinical trials of herbal
products.
-
4.
Pharmacogenetic
work,
building
on
the
HLA-B*35:01
finding,
to
identify
susceptible
individuals
(Hoofnagle et al., 2021).
-
5.
Dose–response
and
formulation
studies
for
concentrated
extracts,
comparing
them
with
traditional
preparations.
-
6.
Better methods for the early detection of herbal nephrotoxicity, including tubular injury biomarkers.
-
7.
Analytical
authentication,
using
chemical
fingerprinting
and
DNA
barcoding,
as
a
routine
requirement for products used in safety studies (Newmaster et al., 2013).
Table 4. Summary of evidence gaps and proposed responses
|
Gap
|
Why it matters
|
Proposed response
|
|
Harms
under-reported
in trials
|
Rare
events
are
never
detected
|
Pre-specified
safety
outcomes;
liver
and
kidney
monitoring
|
|
Weak
spontaneous
reporting
|
Signals are noticed late
|
Herbal
modules
in
national
pharmacovigilance
systems
|
|
Unverified
products
in
case reports
|
Wrong plant may be blamed
|
Mandatory chemical and DNA authentication
|
|
Weak
causality
assessment
|
False
alarms
and
false
reassurance
|
Routine
use
of
RUCAM-type
tools;
standardised
templates
|
|
No renal registry
|
Kidney
harm
remains
invisible
|
Establish herbal nephrotoxicity registries; add herb
history to renal work-up
|
Niranjan Giri
/
International Journal of Pharmaceutical Research and Medicinal Plants
2026, Vol. 2 (5), 12-26
https://informativejournals.com/journal/index.php/Journal_Medicinal_Plants
Page | 21
|
Gap
|
Why it matters
|
Proposed response
|
|
Inconsistent regulation
|
Same
product
treated
differently across borders
|
Harmonised
minimum
safety
and
quality
requirements
|
14. LIMITATIONS OF THIS REVIEW
This is a narrative review, and although the search was structured, it was not exhaustive, and some relevant
reports may have been missed. The evidence grading is qualitative and reflects the authors’ judgment. Most
evidence
comes
from
case
reports
and
series,
which
cannot
establish
incidence
or
confirm
causation.
Publication bias may also over-represent striking cases. For all these reasons the summary of evidence should
be read as a guide to the strength of signals, not as a measure of risk.
15. CONCLUSION
I feel the evidence reviewed here does not support the idea that natural productsre safe. Several used herbs,
such as green tea extract, turmeric supplements, ashwagandha, Tinospora cordifolia, kava for the liver and
Aristolochia
species
for
the
kidney
have
credible
and
sometimes
well-documented
risks.
Equally
some
suspected connections, such as that with cohosh are weaker than first thought and careful assessment of cause
and effect is required in both directions. The deeper problem lies in the safety evidence itself: harms are
under-reported products are unverified, cause and effect is assessed and kidney injury is barely monitored.
Closing
these
gaps
will
require
registries,
standardised
reporting,
product
authentication
and
stronger
monitoring of drug safety. Until then patients and clinicians should treat products with the same caution, as
any other pharmacologically active substance.
REFERENCES:
-
1.
Anderson, I.B., Mullen, W.H., Meeker, J.E., Khojasteh-Bakht, S.C., Oishi, S., Nelson, S.D. and Blanc,
P.D. (1996) 'Pennyroyal toxicity: measurement of toxic metabolite levels in two cases and review of the
literature',
Annals of Internal Medicine
, 124(8), pp. 726–734.
-
2.
Andrade,
R.J.,
Chalasani,
N.,
Björnsson,
E.S.,
Suzuki,
A.,
Kullak-Ublick,
G.A.,
Watkins,
P.B.,
Devarbhavi, H., Merz, M., Lucena, M.I., Kaplowitz, N. and Aithal, G.P. (2023) 'Drug-induced liver
injury',
Nature Reviews Disease Primers
, 9, article 39.
-
3.
Björnsson, H.K., Björnsson, E.S., Avula, B., Khan, I.A., Jonasson, J.G., Ghabril, M., Hayashi, P.H. and
Navarro, V. (2020) 'Ashwagandha-induced liver injury: a case series from Iceland and the US Drug-
Induced Liver Injury Network',
Liver International
, 40(4), pp. 825–829.
-
4.
Brown,
A.C.
(2017)
'Liver
toxicity
related
to
herbs
and
dietary
supplements:
online
table
of
case
reports. Part 2 of 5 series',
Food and Chemical Toxicology
, 107, pp. 472–501.
-
5.
Chalasani,
N.P.,
Maddur,
H.,
Russo,
M.W.,
Wong,
R.J.
and
Reddy,
K.R.
(2021)
'ACG
clinical
guideline: diagnosis and management of idiosyncratic drug-induced liver injury',
American Journal of
Gastroenterology
, 116(5), pp. 878–898.
-
6.
Chen, C.H., Dickman, K.G., Moriya, M., Zavadil, J., Sidorenko, V.S., Edwards, K.L., Gnatenko, D.V.,
Wu,
L.,
Turesky,
R.J.,
Wu,
X.R.,
Pu,
Y.S.
and
Grollman,
A.P.
(2012)
'Aristolochic
acid-associated
urothelial
cancer in
Taiwan',
Proceedings of
the National
Academy of
Sciences
, 109(21), pp. 8241–
8246.
-
7.
Chen, Z. and Huo, J.R. (2010) 'Hepatic veno-occlusive disease associated with toxicity of pyrrolizidine
alkaloids in herbal preparations',
Netherlands Journal of Medicine
, 68(6), pp. 252–260.
Niranjan Giri
/
International Journal of Pharmaceutical Research and Medicinal Plants
2026, Vol. 2 (5), 12-26
https://informativejournals.com/journal/index.php/Journal_Medicinal_Plants
Page | 22
-
8.
Crescioli, G., Lombardi, N., Bettiol, A., Menniti-Ippolito, F., Da Cas, R., Parrilli, M., Del Santo, P.,
Firenzuoli, F. and Vannacci, A. (2018) 'Acute liver injury following
Garcinia cambogia
weight-loss
supplementation: case series and literature review',
Internal and Emergency Medicine
, 13(6), pp. 857–
872.
-
9.
Danan,
G.
and
Teschke,
R.
(2016)
'RUCAM
in
drug
and
herb
induced
liver
injury:
the
update',
International Journal of Molecular Sciences
, 17(1), article 14.
-
10.
Debelle,
F.D.,
Vanherweghem,
J.L.
and
Nortier,
J.L.
(2008)
'Aristolochic
acid
nephropathy:
a
worldwide problem',
Kidney International
, 74(2), pp. 158–169.
-
11.
Devarbhavi, H., Dierkhising, R., Kremers, W.K., Sandeep, M.S., Karanth, D. and Adarsh, A.B. (2010)
'Single-center experience with drug-induced liver injury from India: causes, outcome, prognosis, and
predictors of mortality',
American Journal of Gastroenterology
, 105(11), pp. 2396–2404.
-
12.
EFSA Panel on Food Additives and Flavourings (2018) 'Scientific opinion on the safety of green tea
catechins',
EFSA Journal
, 16(4), article 5239.
-
13.
Ekor,
M.
(2014)
'The
growing
use
of
herbal
medicines:
issues
relating
to
adverse
reactions
and
challenges in monitoring safety',
Frontiers in Pharmacology
, 4, article 177.
-
14.
European Association
for the Study
of the Liver (EASL) (2019) 'EASL
clinical
practice guidelines:
drug-induced liver injury',
Journal of Hepatology
, 70(6), pp. 1222–1261.
-
15.
Ernst, E. (1998) 'Harmless herbs? A review of the recent literature',
American Journal of Medicine
,
104(2), pp. 170–178.
-
16.
Ernst,
E.
(2002)
'Heavy
metals
in
traditional
Indian
remedies',
European
Journal
of
Clinical
Pharmacology
, 57(12), pp. 891–896.
-
17.
Favreau, J.T., Ryu, M.L., Braunstein, G., Orshansky, G., Park, S.S., Coody, G.L., Love, L.A. and Fong,
T.L.
(2002)
'Severe
hepatotoxicity
associated
with
the
dietary
supplement
LipoKinetix',
Annals
of
Internal Medicine
, 136(8), pp. 590–595.
-
18.
Grollman, A.P.,
Shibutani,
S., Moriya, M., Miller, F.,
Wu, L., Moll, U., Suzuki,
N., Fernandes, A.,
Rosenquist,
T., Medverec, Z., Jakovina, K., Brdar, B., Slade, N., Turesky, R.J., Goodenough, A.K.,
Rieger,
R.,
Vukelic,
M.
and
Jelakovic,
B.
(2007)
'Aristolochic
acid
and
the
etiology
of
endemic
(Balkan) nephropathy',
Proceedings of the National Academy of Sciences
, 104(29), pp. 12129–12134.
-
19.
Halegoua-DeMarzio, D., Navarro, V., Ahmad, J., Avula, B., Barnhart, H., Barritt, A.S., Bonkovsky,
H.L., Fontana, R.J., Ghabril, M., Hoofnagle, J.H., Khan, I., Kleiner, D.E., Phillips, E., Rockey, D.C.,
Serrano, J., Stolz, A. and Vuppalanchi, R. (2023) 'Liver injury associated with turmeric—a growing
problem:
ten
cases
from
the
Drug-Induced
Liver
Injury
Network',
American
Journal
of
Medicine
,
136(2), pp. 200–206.
-
20.
Hoofnagle, J.H., Bonkovsky, H.L., Phillips, E.J., Li, Y.J., Ahmad, J., Barnhart, H., Durazo, F., Fontana,
R.J., Gu, J., Khan, I., Kleiner, D.E., Koh, C., Navarro, V.J., Odin, J.A., Stolz, A., Watkins, P.B. and
Chalasani, N. (2021) 'HLA-B*35:01 and green tea-induced liver injury',
Hepatology
, 73(6), pp. 2484–
2493.
-
21.
Ioannidis, J.P.A., Evans, S.J.W., Gøtzsche, P.C., O’Neill, R.T., Altman, D.G., Schulz, K. and Moher,
D. (2004) 'Better reporting of harms in randomized trials: an extension of the CONSORT statement',
Annals of Internal Medicine
, 141(10), pp. 781–788.
-
22.
Isnard Bagnis, C., Deray, G., Baumelou, A., Le Quintrec, M. and Vanherweghem, J.L. (2004) 'Herbs
and the kidney',
American Journal of Kidney Diseases
, 44(1), pp. 1–11.
Niranjan Giri
/
International Journal of Pharmaceutical Research and Medicinal Plants
2026, Vol. 2 (5), 12-26
https://informativejournals.com/journal/index.php/Journal_Medicinal_Plants
Page | 23
-
23.
Izzo,
A.A.
and
Ernst,
E.
(2009)
'Interactions
between
herbal
medicines
and
prescribed
drugs:
an
updated systematic review',
Drugs
, 69(13), pp. 1777–1798.
-
24.
Jaeschke, H., McGill, M.R. and Ramachandran, A. (2012) 'Oxidant stress, mitochondria, and cell death
mechanisms in
drug-induced liver injury: lessons learned from acetaminophen hepatotoxicity',
Drug
Metabolism Reviews
, 44(1), pp. 88–106.
-
25.
Jha, V. (2010) 'Herbal medicines and chronic kidney disease',
Nephrology
, 15(Suppl 2), pp. 10–17.
-
26.
Larrey, D., Vial, T., Pauwels, A., Castot, A., Biour, M., David, M. and Michel, H. (1992) 'Hepatitis
after
germander
(
Teucrium
chamaedrys
)
administration:
another
instance
of
herbal
medicine
hepatotoxicity',
Annals of Internal Medicine
, 117(2), pp. 129–132.
-
27.
Luyckx,
V.A.
and
Naicker,
S.
(2008)
'Acute
kidney
injury
associated
with
the
use
of
traditional
medicines',
Nature Clinical Practice Nephrology
, 4(12), pp. 664–671.
-
28.
Mazzanti,
G.,
Menniti-Ippolito,
F.,
Moro,
P.A.,
Cassetti,
F.,
Raschetti,
R.,
Santuccio,
C.
and
Mastrangelo, S. (2009) 'Hepatotoxicity from green tea: a review of the literature and two unpublished
cases',
European Journal of Clinical Pharmacology
, 65(4), pp. 331–341.
-
29.
Nagral, A., Adhyaru, K., Rudra, O.S., Gharat, A. and Bhandare, S. (2021) 'Herbal immune booster-
induced liver injury in the COVID-19 pandemic: a case series',
Journal of Clinical and Experimental
Hepatology
, 11(6), pp. 732–738.
-
30.
Navarro, V.J., Barnhart, H., Bonkovsky, H.L., Davern, T., Fontana, R.J., Grant, L., Reddy, K.R., Seeff,
L.B., Serrano, J., Sherker, A.H., Stolz, A., Talwalkar, J., Vega, M. and Vuppalanchi, R. (2014) 'Liver
injury
from
herbals
and
dietary
supplements
in
the
US
Drug-Induced
Liver
Injury
Network',
Hepatology
, 60(4), pp. 1399–1408.
-
31.
Navarro, V.J., Khan, I., Björnsson, E., Seeff, L.B., Serrano, J. and Hoofnagle, J.H. (2017) 'Liver injury
from herbal and dietary supplements',
Hepatology
, 65(1), pp. 363–373.
-
32.
Newmaster,
S.G.,
Grguric,
M.,
Shanmughanandhan,
D.,
Ramalingam,
S.
and
Ragupathy,
S.
(2013)
'DNA
barcoding
detects
contamination
and
substitution
in
North
American
herbal
products',
BMC
Medicine
, 11, article 222.
-
33.
Nortier, J.L., Martinez, M.C., Schmeiser, H.H., Arlt, V.M., Bieler, C.A., Petein, M., Depierreux, M.F.,
De
Pauw,
L.,
Abramowicz,
D.,
Vereerstraeten,
P.
and
Vanherweghem,
J.L.
(2000)
'Urothelial
carcinoma associated with the use of a Chinese herb (
Aristolochia fangchi
)',
New England Journal of
Medicine
, 342(23), pp. 1686–1692.
-
34.
Omar, H.R., Komarova, I., El-Ghonemi, M., Fathy, A., Rashad, R., Abdelmalak, H.D., Yerramadha,
M.R., Ali, Y., Helal, E. and Camporesi, E.M. (2012) 'Licorice abuse: time to send a warning message',
Therapeutic Advances in Endocrinology and Metabolism
, 3(4), pp. 125–138.
-
35.
Patel-Rodrigues,
P.A.,
Cundra,
L.,
Alhaqqan,
D.,
Gildea,
D.T.,
Woo,
S.M.
and
Lewis,
J.H.
(2024)
'Herbal- and dietary-supplement-induced liver injury: a review of the recent literature',
Livers
, 4(1), pp.
94–118.
-
36.
Philips,
C.A.,
Ahamed,
R.,
Rajesh,
S.,
George,
T.,
Mohanan,
M.
and
Augustine,
P.
(2020)
'Comprehensive
review
of
hepatotoxicity
associated
with
traditional
Indian
Ayurvedic
herbs',
World
Journal of Hepatology
, 12(9), pp. 574–595.
-
37.
Philips, C.A., Paramaguru, R., Joy, A.K., Antony, K.L. and Augustine, P. (2018) 'Clinical outcomes,
histopathological
patterns
and
chemical
analysis
of
Ayurveda
and
herbal
medicine
associated
with
Niranjan Giri
/
International Journal of Pharmaceutical Research and Medicinal Plants
2026, Vol. 2 (5), 12-26
https://informativejournals.com/journal/index.php/Journal_Medicinal_Plants
Page | 24
-
severe
liver
injury—a
single-center
experience
from
southern
India',
Indian
Journal
of
Gastroenterology
, 37(1), pp. 9–17.
-
38.
Popat, A., Shear, N.H., Malkiewicz, I., Stewart, M.J., Steenkamp, V., Thomson, S. and Neuman, M.G.
(2001)
'The
toxicity
of
Callilepis
laureola
,
a
South
African
traditional
herbal
medicine',
Clinical
Biochemistry
, 34(3), pp. 229–236.
-
39.
Posadzki,
P.,
Watson,
L.
and
Ernst,
E.
(2013)
'Contamination
and
adulteration
of
herbal
medicinal
products (HMPs): an overview of systematic reviews',
European Journal of Clinical Pharmacology
,
69(3), pp. 295–307.
-
40.
Saper, R.B., Phillips, R.S., Sehgal, A., Khouri, N., Davis, R.B., Paquin, J., Thuppil, V. and Kales, S.N.
(2008) 'Lead, mercury, and arsenic in US- and Indian-manufactured Ayurvedic medicines sold via the
internet',
JAMA
, 300(8), pp. 915–923.
-
41.
Sarma, D.N., Barrett, M.L., Chavez, M.L., Gardiner, P., Ko, R., Mahady, G.B., Marles, R.J., Pellicore,
L.S., Giancaspro, G.I. and Low Dog, T. (2008) 'Safety of green tea extracts: a systematic review by the
US Pharmacopeia',
Drug Safety
, 31(6), pp. 469–484.
-
42.
Shaw, D. (2010) 'Toxicological risks of Chinese herbs',
Planta Medica
, 76(17), pp. 2012–2018.
-
43.
Sheikh, N.M., Philen, R.M. and Love, L.A. (1997) 'Chaparral-associated hepatotoxicity',
Archives of
Internal Medicine
, 157(8), pp. 913–919.
-
44.
Shen, T., Liu, Y., Shang, J., Xie, Q., Li, J., Yan, M., Xu, J., Niu, J., Liu, J., Watkins, P.B., Aithal, G.P.,
Andrade, R.J., Dou, X., Yao, L., Lv, F., Wang, Q., Li, Y., Zhou, X., Zhang, Y., Zong, P., Wan, B., Zou,
Z., Yang, D., Nie, Y., Li, D., Wang, Y., Han, X., Zhuang, H., Mao, Y. and Chen, C. (2019) 'Incidence
and etiology of drug-induced liver injury in mainland China',
Gastroenterology
, 156(8), pp. 2230–2241.
-
45.
Stickel,
F.
and
Shouval,
D.
(2015)
'Hepatotoxicity
of
herbal
and
dietary
supplements:
an
update',
Archives of Toxicology
, 89(6), pp. 851–865.
-
46.
Teschke, R. and Eickhoff, A. (2015) 'Herbal hepatotoxicity in traditional and modern medicine: actual
key issues and new encouraging steps',
Frontiers in Pharmacology
, 6, article 72.
-
47.
Teschke, R., Frenzel, C., Glass, X., Schulze, J. and Eickhoff, A. (2013) 'Herbal hepatotoxicity: a critical
review',
British Journal of Clinical Pharmacology
, 75(3), pp. 630–636.
-
48.
Teschke, R., Sarris, J. and Schweitzer, I. (2012) 'Kava hepatotoxicity in traditional and modern use: the
presumed Pacific kava paradox hypothesis revisited',
British Journal of Clinical Pharmacology
, 73(2),
pp. 170–174.
-
49.
Teschke,
R.,
Schwarzenboeck,
A.,
Schmidt-Taenzer,
W.,
Wolff,
A.
and
Hennermann,
K.H.
(2011)
'Herb induced liver injury presumably caused by black cohosh: a survey of initially purported cases and
herbal quality specifications',
Annals of Hepatology
, 10(3), pp. 249–259.
-
50.
Vanherweghem,
J.L.,
Depierreux,
M.,
Tielemans,
C.,
Abramowicz,
D.,
Dratwa,
M.,
Jadoul,
M.,
Richard, C., Vandervelde, D., Verbeelen, D., Vanhaelen-Fastre, R. and Vanhaelen, M. (1993) 'Rapidly
progressive
interstitial
renal
fibrosis
in
young women:
association
with
slimming
regimen
including
Chinese herbs',
The Lancet
, 341(8842), pp. 387–391.
-
51.
Wiedenfeld, H. (2011) 'Plants containing pyrrolizidine alkaloids: toxicity and problems',
Food Additives
and Contaminants: Part A
, 28(3), pp. 282–292.
-
52.
World
Health
Organization
(2004)
WHO
guidelines
on
safety
monitoring
of
herbal
medicines
in
pharmacovigilance systems
. Geneva: WHO.
Niranjan Giri
/
International Journal of Pharmaceutical Research and Medicinal Plants
2026, Vol. 2 (5), 12-26
https://informativejournals.com/journal/index.php/Journal_Medicinal_Plants
Page | 25
-
53.
World
Health
Organization
(2007)
WHO
guidelines
for
assessing
quality
of
herbal
medicines
with
reference to contaminants and residues
. Geneva: WHO.
-
54.
World
Health
Organization
(2019)
WHO
global
report
on
traditional
and
complementary
medicine
2019
. Geneva: WHO.
-
55.
Yüce,
B.,
Gülberg,
V.,
Diebold,
J.
and
Gerbes,
A.L.
(2006)
'Hepatitis
induced
by
Noni
juice
from
Morinda citrifolia
: a rare cause of hepatotoxicity or the Noni phenomenon?',
Scandinavian Journal of
Gastroenterology
, 41(9), pp. 1086–1090.
How to cite this article:
Niranjan Giri, Umesh Maske, Hepatotoxicity and Nephrotoxicity of Widely Used Medicinal Herbs: A Critical
Appraisal
of
Safety
Evidence
Against
the
Assumption
That
“Natural”
Means
Safe.
(2026).
International
Journal
of
Pharmaceutical
Research and Medicinal Plants
,
2
(5)12-26.
https://doi.org/10.61280/89qdmp44
Published by:
Informative Journals
Jadoun Science Publishing Group India
Niranjan Giri
/
International Journal of Pharmaceutical Research and Medicinal Plants
2026, Vol. 2 (5), 12-26
https://informativejournals.com/journal/index.php/Journal_Medicinal_Plants
Page | 26